Company: HROW
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001641172-25-009263
Chunk: 60

Company: HARROW, INC.
Filing Date: 2025-05-08
Form: 10-Q
Item: Item 2
Chunk 60
---
 or mitigate any potential regulatory-related
restrictions, optimize pricing and obtain reimbursement options for our drug products, and continue to pursue development and commercialization
opportunities for certain of our ophthalmology and other assets that we have not yet made commercially available. We believe we have built
a tangible and intangible infrastructure that will allow us to scale revenues efficiently in the near and long-term. All of these activities
may require significant costs and other resources, which we may not have or be able to obtain from operations or other sources. See “Liquidity
and Capital Resources” below.

 26 

Recent Developments

The
following describes certain developments in 2025 to date that are important to understand our financial condition and results of operations.
See the notes to our unaudited condensed consolidated financial statements included in this Quarterly Report for additional information
about each of these developments.

VEVYE Access for All

In March 2025, we announced
a patient access program called VEVYE Access for All.  The program is designed to increase patient access to VEVYE at an out-of-pocket
cost of $59 or below and, in many cases, reduce the need for prior authorizations, step edits, and other treatment obstacles facing dry
eye patients and their prescribers.

Project Beagle

During the first quarter of
2025 we initiated a 360-degree review of opportunities to offer ImprimisRx customers a Harrow-owned FDA-approved product alternative to
a compounded formulation. We call this initiative Project Beagle. In that vein, we began implementing a continuity of care program to
transition approximately 25,000 ImprimisRx patients from our Klarity-C (0.1% cyclosporine) compounded formulation to VEVYE (0.1% cyclosporine),
and we expect to discontinue compounding Klarity-C by June 30, 2025.  We are also discontinuing another related compounded formulation
called Klarity PF. Klarity PF is primarily purchased by a concentrated group of customers who we anticipate will accept our FRESHKOTE
product as an alternative. As we work through Project Beagle, we will continue to review opportunities to reduce the size of our compounded
formulary, improve and simplify our compounding capabilities, and transition other ImprimisRx customers from compounded formulations to
Harrow’s FDA-approved products.

Results of Operations

The following period-to-period
comparisons of our financial results for the three months ended